Desktop Genetics, a UK-based bioinformatics company, said this week that it will use £375,000 ($582,000) in funding to further develop and commercialize AutoClone, its flagship software product for designing, constructing, managing, and exchanging DNA constructs.
The funds come from an equity investment of £275,000 from Boundary Capital, Execute Technologies, and four angel investors. The firm also received an additional £100,000 from a technology strategy board grant.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
